HER2 overexpression or amplification is observed in approximately 10–16% of gallbladder cancer and 5–11% of extrahepatic bile duct cancer [3–5], although its biologic importance or clinical implication are not as well understood as in breast cancer and gastric cancer [6–8]. This evidence concerns the gene ERBB2 and breast carcinoma.